PRIME LifeTech Secures RMB 100 Million Pre-A Financing and Announces Deep Strategic Partnership with IQVIA

VCBeat has learned that Hangzhou Purui Life Technology Co., Ltd. (hereinafter referred to as “Purui”) recentlyCompleted RMB 100 million in Pre-A financing, led by Qiming Venture Partners and participated by Enran Venture Capital。

This round of financing will be used to furtherIncrease Investment in Digital Technology Innovation for Clinical Research、System Integration with Partner Hospitals/GCP Institutions、Building a Digital Business Operations and Delivery Team, andInternet Hospital Development, thereby achieving a digital and intelligent transformation of globally leading clinical research and commercial operation models in the biopharmaceutical industry.

Wang Zheng, Founder, Chairman and CEO of Purui“Qiming Venture Partners boasts extensive resources in the healthcare sector and has invested in numerous biopharmaceutical technology and R&D innovation enterprises, many of which are leaders in their respective niche markets. These companies represent natural high-quality clients and ecosystem partners for Purui’s future growth. Our collaboration with Qiming Venture Partners will bring us more advanced business concepts and premium core resources, thereby facilitating the company’s rapid expansion in the years to come.”

PuRui was established in January 2021, with global CRO giant IQVIA as its co-founding partner. PuRui is committed to building a big data federation cooperation network covering the entire health lifecycle. By leveraging digital technology innovation and the deep application of artificial intelligence, it leads the transformation of clinical research operations for pharmaceuticals, biologics, and medical devices, as well as pharmaceutical commercial operations and digital health service models.

Wang Zheng, Founder and CEO of Purui, holds an M.D. from Shanghai Jiao Tong University and an MBA from Duke University in the United States. With five years of experience as a cardiac surgeon, he previously served as a healthcare consulting partner in both China and the United States. He joined IQVIA in 2017, where he successively led strategic planning and mergers & acquisitions for Greater China and the Asia-Pacific region, demonstrating extensive expertise in end-to-end solutions ranging from clinical research to commercial consulting services.

At the inception of his venture, Wang Zheng clearly recognized that China’s booming biopharmaceutical technological innovation was generating significant globalization opportunities. There is an urgent need in the Chinese market for digital innovative solutions that not only demonstrate a deep understanding of local business models and meet regulatory requirements but also align with international technical, quality, and compliance standards for global clinical research and commercial services.

PuRui is committed to becoming such an innovative enterprise that combines a global vision for innovation with the capability to localize and digitally transform innovative technologies in China.

The outbreak of the pandemic in 2020 brought traditional offline clinical research operations to a standstill, serving as a catalyst for the establishment of PuRui. In January 2021, PuRui Life Sciences was registered and established in Hangzhou, positioning itself as a Chinese domestic healthcare technology company built in accordance with global industry standards, with IQVIA providing technical operations and commercial support to PuRui.

As a global leader in human health data science and technology, IQVIA provides services spanning clinical research, commercial consulting, and technological innovation. As IQVIA’s strategic investment vehicle and hub for commercial innovation in China, Purui stands on the shoulders of a giant, embracing diverse global perspectives while rooting its efforts in localized innovative technologies. This approach enables the deep application of big data and artificial intelligence in the healthcare sector across China and worldwide.

Dr. Mi Zihou, President of IQVIA Asia Pacific, stated, “PuRui is an incubated enterprise of IQVIA in China and a close strategic partner of ours. IQVIA holds electronic medical record data for approximately one billion patients worldwide, accounting for nearly 9% of the global population. The establishment of PuRui enables us to engage in deeper collaboration with hospitals and government agencies. We apply globally proven methodologies to China to facilitate the digital transformation of clinical trials. The systems developed by PuRui can accelerate the digitalization of clinical trials in hospitals. Through our strategic partnership, we aim to enhance the efficiency of clinical research and reduce resource waste.”

Combining a global perspective with the capacity for digital transformation and technology transfer in China, Purui has disrupted traditional manual interventions by developing a digital clinical research system that complies with NMPA, US FDA, EMA, and ICH-GCP standards. This system enables paperless, remote, and intelligent processes for study data entry, governance, information processing, and monitoring, systematically enhancing data quality, operational efficiency, and regulatory compliance in data management.

Meanwhile, Purui’s unified technical standards solution will establish a research network platform that connects internal and external hospital operations across institutions. By leveraging technologies such as digital real-world databases, data insight research, medical information and pharmacovigilance, and digital health (combining private-domain health management with digital therapeutics), it will achieve comprehensive lifecycle data integration and health management, spanning from in-hospital to out-of-hospital settings and from patients to the general healthy population.

Digital Intelligent Full-Lifecycle Solution

According to Wang Zheng, Purui’s core business scenarios revolve around a digitalized, intelligent full lifecycle, which can be broadly summarized as"4+4" Solutions for R&D and Commercialization.

PuRui Digital Intelligent Clinical Research Accelerator (Prime DIRECT)^TMSolution) is a next-generation innovative clinical research solution globally, characterized by remote operation, digitalization, centralization, and intelligence. It achieves a patient-centric approach by leveraging artificial intelligence and digital technologies to replace traditional manual methods, providingIntelligent Medical Record Retrieval, Intelligent Remote Data Collection, Centralized Remote Intelligent Monitoring, Digital Remote Subject ManagementInformed Consent and ComplianceFour Major Solutions Dedicated to Enhancing Hospitals’ Research Capabilities and Improving the Efficiency of Clinical Trials for Pharmaceutical Companies

The Purui Intelligent Remote Data Collection and Monitoring System transforms the traditional manual data collection approach by Clinical Research Coordinators (CRCs). Leveraging point-to-point system integration along with collaborative support from Optical Character Recognition (OCR) and Natural Language Processing (NLP), it achieves 70% or higher automation in data entry assisted by artificial intelligence, thereby enabling automatic acquisition of hospital clinical data and its archiving into the Electronic Data Capture (EDC) system.

The Clinical Remote Intelligent Monitoring Center has achieved platform-based integration, enabling a real-time remote data monitoring system that connects to multiple hospitals. First, it significantly reduces the frequency and time of travel for Clinical Research Associates (CRAs), greatly improving the speed and efficiency of data entry. Second, the point-to-point linkage of the digital system ensures end-to-end electronic traceability of data, preserving a complete audit trail. This supports Risk-Based Quality Management (RBQM) and maximizes the prevention of data tampering and entry errors. Furthermore, the central platform is equipped with rigorous data de-identification, privacy protection, and 24/7 data surveillance systems, which substantially mitigate data security risks associated with traditional manual data transcription. Finally, the aggregation of these value propositions significantly enhances cost-effectiveness and accelerates clinical research. According to incomplete statistics from early pilot programs of remote monitoring in Australian clinical trials, more than 60% of data monitoring-related costs can be saved.

In addition to the clinical research sector, Purui is also committed to buildingDigital Intelligent Health Community — Prime X Community^TM, leveraging the traffic from public-domain collaborative health-themed short videos to build a high-engagement private domain for patient and healthy population health management topics; by equipping digital therapeutics management tools and self-reporting applications, constructing digital twins of individual out-of-hospital health behaviors, and combining Precise Clinical Research’s digital technology and insights on the clinical research side, providing aroundDigital Real-World Database, Data Insight Research, Medical Information ServiceswithDigital HealthFour Major Service Categories.

As an integrated platform, digital health consolidates modules such as the aforementioned database research, real-world studies, patient-reported outcomes (PROs), and internet hospital call centers. It provides enterprises with services including patient health management, physician education, and B-side traffic monetization, thereby assisting companies in delivering patient disease education and guiding perceptions regarding health products, prescription medical devices, and pharmaceuticals.

Wang Zheng stated, “Our clinical research accelerator and digital intelligent health community will comprehensively enhance the decision-making and operational efficiency of business activities related to drug and medical device development and health management, covering every stage from clinical R&D to commercial operations, with significant scalability and promising future prospects.”

Currently, Purui has completed the establishment of its product and talent frameworks. The company has assembled a team of outstanding core professionals, with founders hailing from top-tier organizations such as IQVIA, WuXi AppTec, Google, Pfizer, and Winning Health. It has also attracted numerous leading industry experts in digital therapeutics and data science.

Wang Zheng stated, “Given the complexity and depth of our company’s client base and service offerings, we have recruited top-tier talent from each specialized sector. Currently, more than half of our team comprises product, R&D, and medical science professionals, with R&D expenditure accounting for over 60% of our total spending. We are confident in the technological leadership and competitiveness of our products.”

“Purui’s core competitiveness lies first in our globally minded, locally rooted talent team. Second, we rigorously adopt the industry’s highest international standards for technical architecture, quality systems, and safety and compliance frameworks—sparing no expense in these investments. The technology systems and solutions co-developed with IQVIA, a benchmark international CRO, equip us with the qualifications and capabilities to serve global CROs and pharmaceutical and medical device manufacturers. This gives us confidence in achieving seamless alignment with international standards across technology development, product operations and maintenance, and commercial services,” said Wang Zheng.

PRIME, which stands for Patient Research, Intelligent & Management Empowerment, reflects the original intention behind the founding of PuRui. The company aims to enhance patient research, patient insights, patient management, and health empowerment through digitalization and artificial intelligence, thereby delivering the world’s best treatments to patients in a faster, better, and more cost-effective manner.

“From the perspective of the company’s development trajectory, 2021 marked the inaugural year for Purui, and in 2022, Purui will enter a fast track of rapid growth. I hope that Purui will make solid progress in the new year and quickly grow into a leader in innovation within the medical field,” said Wang Zheng.

IQVIA is a global leader in providing advanced analytics, technology solutions, and clinical research services dedicated to the life sciences industry. IQVIA was formed through the merger of Quintiles and IMS Health. By leveraging deep analytics, cutting-edge technology, big data resources, and extensive domain expertise, IQVIA intelligently connects every link in the healthcare ecosystem. It delivers powerful data insights to clients with speed and agility, helping them accelerate the clinical development and commercialization of innovative therapies, thereby improving patient outcomes. IQVIA employs approximately 74,000 people and operates in more than 100 countries and regions.

Qiming Venture Partners was established in 2006 and has successively set up offices in Shanghai, Beijing, Suzhou, Hong Kong, Seattle, Boston, and the San Francisco Bay Area. Currently, Qiming Venture Partners manages ten US dollar funds and six RMB funds, with total assets under management reaching $6.2 billion. Since its inception, the firm has focused on investing in outstanding early-stage and growth-stage companies in industries such as TMT and Healthcare. To date, Qiming Venture Partners has invested in more than 430 high-growth innovative enterprises, among which over 170 have achieved exits through listings on exchanges including the New York Stock Exchange (NYSE), NASDAQ, Hong Kong Stock Exchange (HKEX), Taipei Exchange (TPEx), Shanghai Stock Exchange (SSE), and Shenzhen Stock Exchange (SZSE), as well as through mergers and acquisitions. More than 40 of these portfolio companies have become industry-recognized unicorns and super unicorns.

Enran Venture Capital was established in 2015. It strategically invests in revolutionary new technologies and products across the global biomedical and healthcare industry chains, striving to become a professional investment institution in the biomedical and healthcare sectors. The company’s management team and investors possess extensive investment experience and deep industrial resources in the biomedical and healthcare fields, while focusing on the commercial value generated by the integration of “life,” “health,” and “innovation.” Enran Venture Capital specializes in life sciences, healthcare, and innovation, and is committed to serving as an investor, partner, and co-founder to its portfolio companies.